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MaOBJECTIVES The aim of this study was to evaluate a strategy of intentional underexpansion of excessively oversized
balloon-expandable transcatheter heart valves (THVs) in termsof clinical outcomes, valve function, and framedurability at 1 year.
BACKGROUND Transcatheter aortic valve replacement requires the selection of an optimally sized THV to ensure
paravalvular sealing and ﬁxation without risking annular injury. However, some patients have “borderline” annular di-
mensions that require choosing between a THV that may be too small or another that may be too large.
METHODS We evaluated 47 patients at risk of annular injury who underwent transcatheter aortic valve replacement
(TAVR) with an oversized, but deliberately underexpanded, THV followed by post-dilation if required. Clinical evaluation,
echocardiography, and cardiac computed tomography were performed pre-TAVR, post-TAVR, and at 1 year.
RESULTS Deployment of oversized THVs with modest underﬁlling of the deployment balloon (<10% by volume)
was not associated with signiﬁcant annular injury. Paravalvular regurgitation was mild or less in 95.7% of patients, with
post-dilation required in 10.7%. THV hemodynamic function was excellent and remained stable at 1 year. Computed
tomography documented stent frame circularity in 87.5%. Underexpansion was greatest within the intra-annular THV
inﬂow (stent frame area 85.8% of nominal). There was no evidence of stent frame recoil, deformation, or fracture at
1 year.
CONCLUSIONS In carefully selected patients with borderline annulus dimensions and in whom excessive oversizing of
a balloon-expandable SAPIEN XT valve (Edwards Lifesciences, Inc., Irvine, California) is a concern, a strategy of deliberate
underexpansion, with ad hoc post-dilation, if necessary, may reduce the risk of annular injury without compromising valve
performance. (J Am Coll Cardiol Intv 2015;8:1727–32) © 2015 by the American College of Cardiology Foundation.m the *St. Paul’s Hospital, Vancouver, British Columbia, Canada; and the yAarhus University Hospital, Aarhus, Denmark. Drs.
eung, Dvir, Lauck, Leipsic, Webb, Wood, and Ye have received consulting fees and grant support from Edwards Lifesciences, Inc.
. Hansson and Norgaard have received grant support from Edwards Lifesciences, Inc. Drs. Blanke and Moss have been consultants
Edwards Lifesciences, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to
close.
nuscript received February 9, 2015; revised manuscript received June 3, 2015, accepted August 3, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
CT = computed tomography
NYHA = New York Heart
Association
PVR = paravalvular
regurgitation
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve
TTE = transthoracic
echocardiogram
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1728T ranscatheter aortic valve replace-ment (TAVR) is a proven alternativeto conventional surgical aortic valve
replacement (1). Selection of an appropriately
sized transcatheter heart valve (THV) is a
complex component of the TAVR procedure.
Excessive undersizing may lead to paravalv-
ular regurgitation (PVR) and poor device
ﬁxation (2–4). Excessive oversizingmay result
in coronary obstruction, atrioventricular
block, mitral valve injury, periaortic hema-
toma, septal rupture, or aortic root rupture
(4,5). Aortic annular rupture has proved to bea particular concern when oversizing with balloon-
expandable valves (6).SEE PAGE 1733SAPIEN XT and SAPIEN 3 balloon-expandable THVs
(Edwards Lifesciences, Inc., Irvine, California) are
manufactured in 4 sizes, with nominal expanded di-
ameters of 20, 23, 26, and 29 mm. The manufacturer’s
sizing guidelines allow for a gray area with consid-
erable overlap, where patients with “borderline”
annular dimensions may be candidates for either of 2
available THV sizes. Often neither of the 2 sizes is
ideal; the smaller THV may result in undersizing, and
the larger THV may result in excessive oversizing.
The difﬁculty is compounded by the uncertainty
involved in noninvasively estimating aortic annular
dimensions and compliance as well as the presence of
adverse aortic root features (such as subannular
calciﬁcation) (7).
In such difﬁcult clinical scenarios in which
optimal sizing cannot be achieved, we previously
described a strategy of deliberate THV stent under-
expansion by reducing the volume of the deploy-
ment balloon (7). The risk of annular injury is
potentially reduced, and the underexpanded valve
can subsequently be post-dilated and fully expanded
if assessment of PVR suggests that this is necessary
and safe. We demonstrated that underﬁlling the
deployment balloon by 5% to 10% resulted in a pre-
dictable reduction in THV expansion. Although this
strategy showed no adverse effects on short-term
clinical or echocardiographic outcomes, questions
remain regarding the intermediate- and long-term
durability of underexpanded THVs.
To further increase our understanding of clinical
outcomes and the durability of underexpanded THVs,
we undertook 12-month clinical, echocardiographic,
and computed tomography (CT) follow-up of a cohort
of patients at increased risk of annular injury who
underwent TAVR with an underﬁlled deployment
balloon.METHODS
Forty-seven consecutive patients with severe aortic
stenosis and borderline annular sizing at risk of
annular injury who underwent TAVR with an inten-
tionally underexpanded SAPIEN type balloon-
expandable THV were included in this prospective
study at 2 centers. Our criteria for intentional THV
underexpansion were previously reported (7). These
included >20% predicted annular area oversizing or
>10% predicted annular area oversizing in patients
with adverse root features (moderate to severe left
ventricular outﬂow tract calciﬁcation, shallow
sinuses of Valsalva), extreme age, previous chest
irradiation, or relatively small body size. The pre-
dicted oversizing was determined by comparing the
pre-procedural CT-derived annulus area with the
manufacturer’s stated THV cross-sectional area.
Annular area was preferred over annular perimeter
for valve sizing as this measurement has been
shown to predict PVR after balloon-expandable TAVR
more accurately (4). It is recognized that, with
improved smoothing algorithms, perimeter mea-
surements may result in comparable outcomes.
The manufacturer’s recommended nominal ﬁlling
volume of the deployment balloon for the 20-, 23-, 26-,
and 29-mm transfemoral Novaﬂexþ delivery system
(Edwards Lifesciences, Inc.) are 11, 17, 22, and 33 ml,
respectively. The nominal ﬁlling volumes for the 23-,
26-, and 29-mmtransapical Ascendraþdelivery system
(Edwards Lifesciences, Inc.) are 16, 20, and 30 ml,
respectively. Our strategy was to intentionally
underexpand THVs by underﬁlling the deployment
balloon by 5% to 10%. Table 1 represents a very general
guide to achieving modest underexpansion for
currently available balloon-expandable valves.
All patients underwent pre- and immediate post-
procedure transthoracic echocardiography and car-
diac CT (7). In the present study, we performed
clinical, echocardiographic, and CT assessment at 12
months post-procedure. Clinical follow-up was per-
formed by a telephone interview or clinic visit to
determine the patient’s New York Heart Association
(NYHA) functional class. If the patient was deceased,
a cause of death was obtained from the patient’s
primary care provider or medical records. A trans-
thoracic echocardiogram (TTE) was obtained to assess
mean transaortic pressure gradient, aortic valve area,
PVR, and left ventricular ejection fraction. PVR was
graded as none, mild, moderate, or severe according
to Valve Academic Research Consortium 2 criteria (8).
Noncontrast CT assessment of THV geometry was also
performed. The stent frame of each THV was assessed
at 3 cross-sectional levels (inﬂow, midportion, and
TABLE 1 Balloon Volumes Required to Achieve Modest Underexpansion of
Currently Available Balloon-Expandable Valves
Nominal Balloon
Volume, ml
Final Balloon
Volume, ml
Volume
Subtracted, ml Underﬁlling, %
SAPIEN XT*
20 mm 11 10 1 9.1
23 mm 17 15.5 1.5 9.4
26 mm 22 20 2 9.1
29 mm 33 30 3 9.1
SAPIEN 3*
20 mm 11 10 1 9.1
23 mm 17 15.5 1.5 9.4
26 mm 23 21 2 8.7
29 mm 33 30 3 9.1
*Edwards Lifesciences, Inc., Irvine, California.
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1729outﬂow) in diastole at 75% of the R-R interval.
The minimal external stent diameter, the maximal
external stent diameter, and the external stent area
were measured at each level by tracing along the
external margins of the stent frame. An experienced
level 3 cardiac CT reader measured all stent levels 3
times, and the data represent the mean of the 3
measurements. The CT reader was blinded to the
degree of underﬁlling in addition to all outcome
measures of this study including the TTE as well as
clinical outcome data.
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD. Categorical variables are re-
ported as frequencies and percentages. Continuous
variables were compared using the paired Student
t test. A p value <0.05 was considered signiﬁcant.
Analyses were performed using SPSS statistics soft-
ware version 16.0 (SPSS Inc., Chicago, Illinois).TABLE 2 Baseline Characteristics, Transthoracic
Echocardiographic, and CT Findings (N ¼ 47)
Age, yrs 82.0  7.6
Male 22 (46.8)
STS score, % 7.8  3.5
NYHA functional class
II 8 (17.0)
III or IV 39 (83.0)
GFR <60 ml/min 32 (68.1)
Peripheral vascular disease 6 (12.8)
Permanent pacemaker 6 (12.8)
Extensively calciﬁed aorta 3 (6.4)
Echocardiographic ﬁndings
Mean aortic gradient, mm Hg 46.4  17.7
Aortic valve area, cm2 0.64  0.17
Left ventricular ejection fraction, % 54.1  11.8
Aortic regurgitation $ moderate 5 (10.6)
CT annulus
Maximal diameter, mm 27.7  3.2
Minimal diameter, mm 21.6  2.3
Mean diameter, mm 24.3  3.2
Area, cm2 4.9  0.9
Values are mean  SD or n (%).
CT ¼ computed tomography; GFR ¼ glomerular ﬁltration rate; NYHA ¼ New
York Heart Association; STS ¼ Society of Thoracic Surgeons.RESULTS
The baseline clinical, echocardiographic, and CT
characteristics are summarized in Table 2. The mean
age was 82.0  7.6 years, 53.2% were female, and the
mean Society of Thoracic Surgeons (STS) predicted
risk of mortality was 7.8  3.5%.
Procedural variables are listed in Table 3. Access
was transfemoral in most (91.5%) patients and trans-
apical in 8.5%. The THV implanted was the SAPIEN
XT in 44 of 47 patients (93.6%) and the SAPIEN 3 in
3 (6.4%). The THV deployment balloon was under-
ﬁlled by 1, 2, 3, and 4 ml in 8 (17.0%), 26 (55.3%), 11
(23.4%), and 2 (4.3%) patients, respectively. Post-
dilation was performed in 5 patients (10.7%). PVR
was mild or less in 45 of 47 patients (95.7%). Two
patients (4.3%) had moderate PVR. Complete heart
block developed post-TAVR in 2 patients (4.3%), and
they required placement of a permanent pacemaker.
There were no cases of severe PVR, annular rupture,
or valve embolization.
CLINICAL OUTCOME AT 1 YEAR. At 12 months, 40 of
47 patients (85.1%) were alive. In the 7 patients who
died, the cause of death was cardiac failure in 1, ma-
lignancy in 2, pneumonia in 1, stroke in 1, a fall with
hip fracture in 1, and unknown in 1. Of those alive, 24
of 40 (60.0%) were NYHA functional class I, 7 (17.5%)
were NYHA II, 8 (20.0%) were NYHA functional class
III, and 1 (2.5%) was NYHA functional class IV (limited
by dyspnea secondary to severe lung disease).
ECHOCARDIOGRAPHY AT 1 YEAR. A TTE was ob-
tained in 38 of 40 patients (95%) alive at 12 months.
Two patients (5%) did not return for a repeat TTE dueto frailty. The mean transaortic gradient was 11.6 
3.8 mm Hg immediately post-implantation and 12.5 
6.5 mm Hg at 12 months (p ¼ 0.46). Mean aortic valve
area was 1.6  0.3 cm2 immediately post-implantation
and 1.6  0.4 cm2 at 12 months (p ¼ 0.53). PVR was
mild or less in 45 of 47 patients (95.7%) immediately
post-implantation and in 36 of 38 patients (94.7%)
at 12 months. Two patients had moderate PVR at
12 months. The mean left ventricular ejection fraction
was 53.4  11.8% immediately post-implantation and
55.2  11.5 at 12 months (p ¼ 0.24).
TABLE 3 Procedural Variables
Access
Transfemoral 43 (91.5)
Transapical 4 (8.5)
Prosthesis type
SAPIEN XT* 44 (93.6)
SAPIEN 3* 3 (6.4)
Prosthesis size, mm
20 1 (2.1)
23 7 (14.9)
26 21 (44.7)
29 18 (38.3)
Underﬁlling of deployment balloon, ml
1 8 (17.0)
2 26 (55.3)
3 11 (23.4)
4 2 (4.3)
Post-dilation
Nominal volume in balloon 3 (6.4)
Underﬁlled balloon 2 (4.3)
Paravalvular regurgitation
Mild or less 45 (95.7)
Moderate 2 (4.3)
Severe 0 (0.0)
New permanent pacemaker 2 (4.3)
Valve embolization 0 (0.0)
Valve-in-valve 0 (0.0)
Annular rupture 0 (0.0)
Transvalvular regurgitation 0 (0.0)
Values are n (%). *Edwards Lifesciences, Inc., Irvine, California.
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1730CT AT 1 YEAR. Cardiac CT was performed in 24 of 40
patients (60.0%) alive at 12 months. Of the 16 patients
who did not undergo repeat cardiac CT, 14 of 16
(87.5%) were not local to the implantation site and 2
of 16 (12.5%) lived in a care facility.
The percentage of THV stent expansion (deﬁned
as CT-derived stent frame area divided by the
manufacturer’s nominal stent frame area  100) is
shown in Figure 1A. THV expansion immediately
post-implantation and at 12 months was 85.8  5.9%
and 85.5  6.3%, respectively at the stent inﬂow
(p ¼ 0.46), 88.9  6.3% and 89.4  5.8%, respectively,
at midstent (p ¼ 0.15), 92.4  7.1% and 92.4  4.2%,
respectively, at stent outﬂow (p ¼ 0.33).
The percentage of THV eccentricity (deﬁned as:
1  [minimal external stent diameter divided by
maximal external stent diameter]  100) is shown
in Figure 1B. THV eccentricity immediately post-
implantation and at 12 months was 3.2  2.8% and
4.0  4.8%, respectively, at stent inﬂow (p ¼ 0.43), 3.4
 2.9% and 3.7  2.9%, respectively, at midstent
(p ¼ 0.33), 2.4  2.0% and 2.9  1.9%, respectively, at
stent outﬂow (p ¼ 0.12). At 12 months, 23 of 24 THVs(95.8%) were circular (deﬁned as eccentricity <10%)
at the stent inﬂow, 22 of 24 (91.7%) were circular at
midstent, and 24 of 24 (100%) were circular at stent
outﬂow.DISCUSSION
We evaluated outcomes in patients at increased risk
of annular injury who underwent TAVR with an
oversized, intentionally underexpanded balloon-
expandable THV as part of a strategy intended to
mitigate the risk of annular injury and PVR. Early
clinical outcomes were good, with no evidence of
annular injury other than a low (4.3%) need for new
pacemakers. Importantly, valve function was not
compromised.
At 1 year, clinical outcomes were also good. The
1-year mortality rate of 14.9% was comparable to
the 12.3% to 28.2% mortality rates reported in other
reports on high-risk patients (9). The majority of
patients (77.5%) remained in NYHA functional class I
or II. At 1 year, there was no echocardiographic evi-
dence of progressive deterioration of valve function,
with low transvalvular gradients, low rates of PVR,
and no CT evidence of stent recoil, deformation, or
fracture.
The commonly recommended strategy of full ex-
pansion of balloon-expandable THVs is intended to
approximate their nominal diameters (currently 20,
23, 26, or 29 mm). However, in some patients, this
may result in a difﬁcult choice between 2 different
size valves, 1 potentially too large and 1 too small.
These concerns may be greater in patients with fea-
tures that predict an increased risk of annular injury
(e.g., subannular calciﬁcation, irradiation, advanced
age) or PVR (e.g., bulky leaﬂet calciﬁcation, eccen-
tricity). Concerns may be further compounded when
the dimensions of the annulus are uncertain due to
suboptimal annular imaging.
Concerns about underexpanding balloon-expandable
THVs are well founded. In vitro studies have shown
that marked underexpansion of the valve stent frame
can result in frame eccentricity, suboptimal leaﬂet
coaptation, and contact between the leaﬂets and the
frame, potentially affecting hemodynamic perfor-
mance and leaﬂet durability. However, it appears that
modest underexpansion (underﬁlling the deployment
balloon by 5% to 10% by volume) does not have a
major impact on midterm hemodynamic function or
durability.
PARAVALVULAR REGURGITATION. A potential concern
is that suboptimal stent expansion might result in
poor sealing and PVR. However, this sizing strategy
FIGURE 1 THV Stent Expansion and Stent Eccentricity
(A) Stent expansion deﬁned as CT-derived stent frame area divided by the manufacturer’s nominal stent frame area  100. (B) Stent
eccentricity deﬁned as: 1  (CT-derived minimal external stent diameterO CT-derived maximal external stent diameter)  100. There was no
statistically signiﬁcant difference between measures immediately post-implantation and at 12 months (all p values > 0.05). CT ¼ computed
tomography; THV ¼ transcatheter heart valve.
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1731was associated with surprisingly little PVR following
SAPIEN XT implantation. PVR was mild or less in
95.7% of patients immediately post-implantation
and 94.7% of patients at 12 months. No patient had
severe PVR.
Potentially, an oversized but underexpanded THV
may not achieve perfect circularity and may conform
better to a noncircular, calciﬁed annulus. However, if
the selected THV is too small, it might not appose the
annulus well, resulting in PVR, even when fully
expanded. Selecting a larger, but underexpanded,
THV allows for greater ﬂexibility in terms of what can
be accomplished with post-dilation. Perhaps surpris-
ingly, post-dilation was required in only 10.7% of
patients because of residual PVR.
STENT FRAME GEOMETRY. Nombela-Franco et al.
(10) demonstrated a minor degree of acute balloon-
expandable frame recoil as seen on ﬂuoroscopy at
the time of balloon deﬂation. Our group has demon-
strated durable expansion and circularity of balloon-
expandable THV frames at an average of 2.5 years,
with no evidence of late recoil (11). The current study
demonstrates that modest frame underexpansion
does not result in a loss of frame strength sufﬁcient
to result in progressive stent recoil, deformation, orfracture as assessed by matched post-implantation
and 1-year CT imaging.
With modest (<10%) underﬁlling of the deploy-
ment balloon, the inﬂow portion of the stent frame
was the segment with the most marked under-
expansion, with a cross-sectional area w86% of
nominal compared with 92% at the outﬂow. The
smaller inﬂow can likely be attributed to the localized
constraint of the annulus and the fabric sealing cuff.
A localized effect on the stent frame inﬂow might be
considered desirable if the intent is to reduce the risk
of annular injury.
Circularity was generally excellent, although non-
circularity was documented in the stent frame inﬂow
in 1 patient (4.2%) and the midportion in 2 patients
(8.3%). In neither case was there an apparent adverse
effect on valve performance. As discussed previously,
there was no signiﬁcant change in stent frame ec-
centricity at either THV inﬂow, midportion, or
outﬂow at 1 year.
STUDY LIMITATIONS. The relatively small sample
size is a limitation of this study. CT follow-up was
not complete. CT lacks the spatial resolution to
completely exclude stent fracture, although it is
adequate to exclude a displaced fracture. Although
PERSPECTIVES
WHAT IS KNOWN? Selection of an appropriately
sized THV is a complex component of TAVR. Under-
sizing may result in PVR or instability, whereas over-
sizing may result in annular injury. The choice between
a valve that is too small and one that is too large may
be difﬁcult when annular dimensions are uncertain
due to suboptimal annular imaging or in patients at
increased risk of annular injury or PVR.
WHAT IS NEW? We used a strategy of controlled
underexpansion of potentially oversized balloon-
expandable valves in patients with “borderline”
annular dimensions at risk of annular injury. Post-
dilation to achieve nominal expansion was required in
10.7%. The clinical outcomes in 47 patients were good
with favorable hemodynamics, minimal PVR, and no
apparent annular injury. Clinical, echocardiographic,
and CT frame geometry remained durable at 1 year.
WHAT IS NEXT? Further studies are needed to
evaluate the long-term durability of this strategy. In
addition, the emergence of newer valves with better
sealing properties might allow for implantation of
smaller valves and a lesser role for a strategy of
controlled underexpansion.
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1732durability at 12 months post-TAVR is reassuring,
longer term follow-up is required.
In future, newer balloon-expandable THV plat-
forms with improved sealing and a greater variety of
sizes may reduce the need to consider a strategy of
controlled underexpansion. Improved sealing ach-
ieved with the outer sealing skirt incorporated into
the next generation of SAPIEN 3 THV (Edwards Life-
sciences, Inc.) may allow less need for oversizing to
minimize PVR. Should this allow newer sizing stra-
tegies, then a strategy of ad hoc underﬁlling may be
less necessary. There are additional concerns that
underexpansion of the SAPIEN 3 THV may result
in signiﬁcantly less foreshortening, with unknown
implications.
CONCLUSIONS
In carefully selected patients in whom excessive
oversizing or undersizing of a SAPIEN XT THV is a
concern, a strategy of intentional underexpansion
may reduce the risk of annular injury and rupture
without compromising valve performance, durability,
or frame integrity at mid-term follow-up.
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